1. Clinical Overview of Adipotide

Molecule:
Adipotide is a synthetic peptidomimetic homing molecule consisting of:

A prohibitin-targeting domain
A pro-apoptotic motif (KLAKLAK)

Primary innovation: Adipotide selectively binds to blood vessels feeding white adipose tissue, causing apoptosis of those vessels, leading to:

Reduced blood supply to fat cells
Adipocyte shrinkage
Rapid fat loss

Classification:

Adipose-targeted pro-apoptotic peptide
Angiogenesis-inhibiting molecule
Obesity research drug

Status: Not FDA-approved. Investigational only. Human use limited to research settings. Known nephrotoxicity risk (dose-dependent).

2. Mechanisms of Action

Adipotide works by selectively destroying the blood supply of white fat tissue.

2.1 Targeting Prohibitin on Adipose Vascular Endothelium

Adipocyte-associated vasculature expresses elevated prohibitin, a surface protein. Adipotide binds to prohibitin with high specificity.

2.2 Internalization & Mitochondrial Disruption

After binding:

The peptide is internalized into endothelial cells
The KLAKLAK segment disrupts mitochondrial membranes
Endothelial cells undergo apoptosis

2.3 Adipocyte Starvation → Fat Cell Reduction

Destruction of blood vessels:

Cuts nutrient supply
Causes adipocyte apoptosis
Leads to rapid reduction in white fat mass

This is unlike GLP-1 agonists (appetite suppression), AOD-9604 (lipolytic signaling), or SLU-PP-332 (mitochondrial thermogenesis). Adipotide directly eliminates fat cells.

2.4 Rapid Weight-Loss Mechanism

Preclinical primate studies showed: Up to 11% body weight loss in 4 weeks, preferential visceral fat loss, appetite remained unchanged.

2.5 Renal Toxicity Mechanism (Important)

Adipotide is filtered through the kidneys and its apoptotic fragment may accumulate in renal tubular cells, causing:

Elevated creatinine
BUN rise
Electrolyte imbalance
Reversible tubular toxicity

This is the primary clinical concern.

3. Evidence-Supported (Investigational) Applications

3.1 Severe Obesity (Research Only)

Most effective in:

High visceral fat burden
GLP-1-resistant obesity
Insulin-resistant phenotypes

Not for cosmetic fat loss.

3.2 Metabolic Syndrome (Research)

Potential improvements noted in:

Fasting glucose
Triglycerides
Waist circumference
Liver fat infiltration

3.3 GLP-1 Non-Responders (Investigational Use)

Adipotide may assist patients who:

Plateau on semaglutide or tirzepatide
Fail to achieve appetite suppression
Have major visceral fat stores

3.4 Specialized Obesity Cases

Potential future applications (research only):

PCOS with severe insulin resistance
Lipodystrophy
Pre-bariatric weight reduction strategy
Obesity-related orthopedic load reduction

4. Administration Routes & Clinical Protocols

Important: All details below are strictly investigational. Adipotide is not approved for human use.

4.1 Subcutaneous or Intramuscular Injection (Research Context)

Standard Investigational Dose (Primate Model–Derived)

0.5–1 mg/kg SC or IM daily
For 28 days, then off-cycle

Extrapolated human dosing in research settings tends to be far lower to prevent renal toxicity.

4.2 Conservative Human-Derived Research Dosing

(used experimentally with intensive renal monitoring)

0.5–5 mg SC daily, depending on weight
5 days on → 2 days off schedule
Maximum: 4 weeks per cycle

4.3 Slow-Titration Kidney-Safety Protocol

Week 1: 1 mg SC daily
Week 2: 2 mg SC daily
Weeks 3–4: 3–5 mg SC daily

Never exceed 5 mg/day in research settings.

4.4 Cycling

1 cycle = 4 weeks
Off-cycle = minimum 4–8 weeks
Kidney labs must normalize before next cycle

4.5 Hydration Requirements

2.5–3.5 L water daily
Avoid NSAIDs
Limit creatine, high-protein diets

5. Combination Therapy (Peptide Protocol Portal Synergy — Research Only)

Adipotide should NOT be combined with other nephrotoxic agents.

Safe adjuncts include metabolic peptides that do not burden kidneys, such as:

5.1 Adipotide + SLU-PP-332

Synergy via:

Fat-cell apoptosis (Adipotide)
Thermogenesis and mitochondrial activation (SLU-PP-332)

5.2 Adipotide + AOD-9604

Targets:

Apoptosis-induced fat loss
GH-fragment lipolysis pathways

5.3 Adipotide + Tesofensine

Addresses:

Reward-driven eating
Caloric intake regulation

5.4 Adipotide + MOTS-c

Improves:

Mitochondrial resilience
Cellular energy
Insulin sensitivity

Supports metabolism during rapid fat turnover.

5.5 Adipotide + SS-31

May protect against mitochondrial oxidative stress during apoptosis-mediated fat clearance.

NOT recommended: Other pro-apoptotic agents, nephrotoxic medications, high-dose NSAIDs, high-dose diuretics, dehydrating stimulants.

6. Clinical Decision Trees

Decision Tree 1 — Is Adipotide Appropriate (Research Context Only)?

Severe visceral-fat obesity? → POSSIBLE

Non-responder to GLP-1 or tirzepatide? → POSSIBLE

Willing for intensive kidney monitoring? → REQUIRED

History of kidney disease? → DO NOT USE

Cosmetic weight loss? → NOT APPROPRIATE

Decision Tree 2 — Safety & Titration

Creatinine elevated? → HOLD or STOP

Symptoms of dehydration? → INCREASE HYDRATION + HOLD DOSE

GI fatigue or flu-like symptoms? → REDUCE DOSE

Cycle complete? → 4–8 week washout

7. Integrated Treatment Archetypes (Investigational)

Archetype A — Severe Obesity / GLP-1 Failure

Systemic:

Adipotide (low-dose research dosing)
SLU-PP-332
Tesofensine
MOTS-c

Outcome: Breaks metabolic resistance and reduces visceral fat.

Archetype B — Visceral Obesity with Insulin Resistance

Systemic:

Adipotide
AOD-9604
NAD+
Low-insulin diet

Outcome: Reductions in organ-surrounding adiposity.

Archetype C — Pre-Bariatric Intervention (Research)

Systemic:

Adipotide
Low-dose semaglutide or tirzepatide
SLU-PP-332

Outcome: Reduces surgical risk via early fat loss.

8. Expected Research Timelines

Week 1–2Quick reduction in abdominal fullness

Week 2–4Noticeable fat loss

Week 4–6Stabilization (cycle completes)

Post-cycleContinued fat loss for 2–4 weeks due to ongoing apoptosis

Long-termWeight redistributes, less visceral fat

9. Contraindications & Precautions (Critical)

Absolute Contraindications

Kidney disease
History of acute kidney injury
Severe dehydration
Pregnancy
Breastfeeding
Active malignancy (due to apoptosis involvement)

Relative Contraindications

Hypertension
Liver disease
Taking nephrotoxic medications
Prolonged fasting states

10. Adverse Effects

Most common:

Nausea
Fatigue
Injection site soreness
Thirst

Kidney-related (dose-dependent):

Elevated creatinine
Increased BUN
Electrolyte imbalance
Reduced GFR

Rare:

Acute kidney injury
Abdominal cramping
Hypotension due to dehydration

11. Monitoring Guidelines (Mandatory)

Baseline Required

Comprehensive metabolic panel
Creatinine
BUN
GFR
Electrolytes
Hydration status

Weekly During Cycle

Creatinine
BUN
Hydration assessment

Post-cycle (2–4 weeks)

Repeat kidney labs

If creatinine rises → stop immediately.

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Adipotide (FTPP / Prohibitin-Targeting Peptide), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Adipotide (FTPP) Clinical Reference Guide

1. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. Reversal of obesity by targeted ablation of adipose tissue vasculature. Nature Medicine, 10(6), 625–632 (2004).

2. White, A. D., Chan, L., Pasqualini, R., & Arap, W. Adipose tissue vasculature as a therapeutic target for obesity. Current Opinion in Investigational Drugs, 4(10), 1199–1203 (2003).

3. Barnhart, K. F., Christianson, D. R., Hanley, P. W., et al. A prohibitin-targeting peptide [Adipotide] induces rapid weight loss in obese monkeys. Science Translational Medicine, 3(108), 108ra112 (2011).

4. Daquinag, A. C., Zhang, Y., Amaya-Manzanares, F., Simmons, P. J., & Kolonin, M. G. Anatomical targeting of white adipose tissue using a prohibitin-targeting peptide. Pharmacology & Therapeutics, 146, 12–24 (2015).

5. Akerman, M. E., Pilch, J., Peters, D., & Ruoslahti, E. Angiogenesis inhibitors targeting integrins and vascular markers. Seminars in Cancer Biology, 12(2), 99–106 (2002).

6. Arap, W., Pasqualini, R., & Ruoslahti, E. Chemotherapy targeting with peptide-based ligands. Nature Reviews Cancer, 2(7), 521–527 (2002).

7. Kolonin, M. G., & Simmons, P. J. Targeting adipose tissue vasculature to control obesity. Trends in Molecular Medicine, 15(6), 225–233 (2009).

8. Daquinag, A. C., Tseng, C., Salameh, A., Zhang, Y., Amaya-Manzanares, F., & Kolonin, M. G. Targeted induction of apoptosis in endothelial cells causes breast tumor regression. Breast Cancer Research, 14(2), R86 (2012).

9. Lin, Q., Chen, Y., Lv, L., et al. Prohibitin promotes adipose tissue remodeling and systemic metabolic homeostasis. Journal of Clinical Investigation, 129(1), 285–298 (2019).

10. Pilch, J., Brown, D. M., Komatsu, M., et al. Peptides selected for binding to clotted plasma accumulate in murine tumors. Proceedings of the National Academy of Sciences, 103(8), 2800–2804 (2006).

11. Ruoslahti, E. & Rajotte, D. An address system in the vasculature of normal tissues and tumors. Annual Review of Immunology, 18, 777–808 (2000).

12. Mahoney, C. W., et al. Mitochondrial disruption peptides and targeted apoptosis: Mechanistic insights. Cell Death & Differentiation, 22(1), 111–125 (2015).

13. Tseng, C., Daquinag, A. C., et al. The adipose tissue microenvironment as a therapeutic target. Nature Reviews Endocrinology, 10(8), 463–476 (2014).

14. Kolonin, M. G. Brown and white adipose tissue vascularization: Metabolic regulation and therapeutic potential. Physiology, 30(6), 400–408 (2015).

15. Ghorbani, M. & Himms-Hagen, J. Adipose tissue vasculature and metabolic disease. International Journal of Obesity, 21(S3), S25–S28 (1997).